share_log

西南证券4月21日发布研报称，给予恒瑞医药（600276.SH）买入评级。评级理由主要包括：1）业绩和盈利能力稳步提升；2）创新成果持续获批，创新药收入拉动整体业绩稳健增长；3）持续建设行业领先的新技术平台，加强源头创新。（每日经济新闻）

Southwest Securities released a research report on April 21 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) steady improvement in performance and profitability; 2) continuous approval

Zhitong Finance ·  Apr 21 09:40
Southwest Securities released a research report on April 21 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) steady improvement in performance and profitability; 2) continuous approval of innovative achievements, driving steady growth in overall performance; 3) continuing to build industry-leading new technology platforms to strengthen innovation at the source. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment